Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Lialda is a prescription delayed-release mesalamine tablet containing 1.2 grams per tablet. It is indicated for induction and maintenance of remission in adults with mildly to moderately active ulcerative colitis and for treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.
read more about lialda ...The exact mechanism of mesalamine in ulcerative colitis is not fully established. Its activity is mainly topical in the colon, where it reduces inflammatory pathways involving arachidonic acid metabolites and other inflammatory mediators.
Lialda is used in adults with mildly to moderately active ulcerative colitis for induction and maintenance of remission. Pediatric treatment applies to patients weighing at least 24 kg who can swallow the tablets whole. Renal function is checked before treatment and periodically during therapy.
Adults take 2.4 grams to 4.8 grams once daily for induction and 2.4 grams once daily for maintenance. Pediatric dosing is weight-based. Patients weighing 24 kg to 35 kg take 2.4 grams daily for eight weeks, then 1.2 grams daily. Patients above 35 kg to 50 kg take 3.6 grams daily for eight weeks, then 2.4 grams daily. Patients above 50 kg take 4.8 grams daily for eight weeks, then 2.4 grams daily. Tablets are taken with food and swallowed whole.
Serious concerns include kidney impairment, mesalamine-induced acute intolerance syndrome, severe hypersensitivity reactions, liver failure in patients with underlying liver disease, kidney stones, and severe skin reactions. Adequate fluid intake is advised during treatment, especially in patients with a history of kidney stones.
Lialda treats mildly to moderately active ulcerative colitis and is also used for maintenance of remission in adults.
The adult induction dose is 2.4 grams to 4.8 grams once daily.
The adult maintenance dose is 2.4 grams once daily.
No. Lialda tablets are swallowed whole and are not split or crushed.
DailyMed - LIALDA (mesalamine) tablet, delayed release. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7. Date Accessed October 13, 2026.
Mesalamine. MedlinePlus. https://medlineplus.gov/druginfo/meds/a688021.html. Date Accessed October 13, 2026.
Mesalamine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Mesalamine. Date Accessed October 13, 2026.
Mesalamine (USAN). StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK551714/. Date Accessed October 13, 2026.
Search Orphan Drug Designations and Approvals - Lialda. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=253607. Date Accessed October 13, 2026.